Conclusion GLP-1 and its receptor agonists represent a significant advancement in the treatment of metabolic disorders
Additionally, as Zepbound promotes weight loss through reduced appetite and caloric intake, some patients may inadvertently decrease their fluid consumption alongside food intake
10.1186/s13578-017-0178-y 124 SwerdlowS
Other types of GLP-1 agonists include dulaglutide (Trulicity), liraglutide (Saxenda), and tirzepatide (Zepbound and Mounjaro), whose manufacturers are also facing lawsuits
GLP-1 slows digestion and reduces appetite
Ipamorelin Assessment Laboratory assessments evaluate peptide selectivity, receptor binding characteristics, and experimental reproducibility through doseresponse analysis, receptor binding studies, and functional testing